Press
Milford, MA – November 2011
Spring Bank Pharmaceuticals Receives Allowance for US Patent. READ MORE>>>
Milford, MA – May 2011
Spring Bank Pharmaceuticals $3.9 Million RO1 Awarded NIH Grant to Advance Innovative Hepatitis Program.
READ MORE>>>
Milford, MA – February 2011
Dr. Nezam H. Afdhal has joined Spring Pharmaceuticals as Chair of Clinical Advisory Board.
READ MORE>>>
Milford, MA – November 2010
Spring Bank Pharmaceuticals announced today that Guy Macdonald, CEO and President of Tetraphase Pharmaceuticals will join Spring Bank’s Board of Directors.
READ MORE>>>
Milford, MA – November 12, 2010
Dr. Kris Iyer, Chief Scientific Officer and Co-Founder of Spring Bank Pharmaceuticals, Inc. will present an invited talk at the 6th International Symposium on “Innovations in Pharmaceutical Sciences and Technology,” to be held November 26-28, 2010 in Ahmedabad, India.
READ MORE>>>
Milford, MA – November 2010
Spring Bank Pharmaceuticals, Inc. has received a grant of $244,000 under the US Government's Qualifying Therapeutic Discovery Project (QTDP), for its ongoing development SB9200, a novel treatment for Hepatitis C and Hepatitis B.
READ MORE>>>
Milford, MA – February 2010
Spring Bank Pharmaceuticals Presents Study Results for Novel Anti- Viral Pharmaceuticals from its Small Molecule Nucleic Acid Hybrid technology platform
READ MORE>>>
Milford, Ma., July 1, 2009
Spring Bank Pharmaceuticals Awarded NIH Grant for Hepatitis Program
READ MORE>>>
Milford, Ma., March 1, 2009
Spring Bank Pharmaceuticals Completes $600,000 Angel Financing Round
READ MORE>>>
About Hepatitis
Over 350 million people are chronically infected with HBV virus worldwide. The HBV virus is a DNA virus which incorporates into the hepatocyte DNA. Read More >>
Approximately 170 million people worldwide and 4 million in the United States are infected with HCV. HCV infection is one of the most significant public health threats facing Americans.
Read More >>
